Unlocking the Future of Drug Discovery with Artificial Intelligence

Stand Out Facts Stand Out Facts Now is the Time to Act The AI in the Drug Discovery sector is witnessing unprecedented growth, underscored by a significant increase in venture capital funding for AI-driven biotech startups, reaching approximately$1.9 billionin 2020 alone. Although this data is from 2020, it is a testament to the sector's robust expansion. In 2022, the AI startup investment landscape continued to thrive, with 27 deals totaling about$1.94 billion(€1.8 billion)...

Stand Out Facts

Now is the Time to Act

The AI in the Drug Discovery sector is witnessing unprecedented growth, underscored by a significant increase in venture capital funding for AI-driven biotech startups, reaching approximately $1.9 billion in 2020 alone. Although this data is from 2020, it is a testament to the sector's robust expansion. In 2022, the AI startup investment landscape continued to thrive, with 27 deals totaling about $1.94 billion (€1.8 billion) involving pharmaceutical and biotech entities. This growth is further fueled by burgeoning research collaborations between top pharmaceutical companies and AI-focused biotech and technology vendors, coupled with a steady stream of new product releases, scientific discoveries, and proof-of-concept studies.

Venture capital firms, pharmaceutical giants, and technology leaders are making substantial investments in AI for drug discovery, fueling in-depth research and advancements in the field. Collaborations with contract research organizations (CROs), known for their adaptability and specialization, are proving to be an effective strategy for harnessing AI solutions in drug discovery. For example, Pfizer is utilizing the supercomputer IBM Watson and machine learning and deep learning technologies to develop innovative immuno-oncology medications. Sanofi and Exscientia have also joined forces to explore treatments for metabolic disorders using advanced AI technology.

Learn More Today

The global market for AI in drug discovery is estimated at $1.2 million in 2022 and is expected to grow at a CAGR of 29.6% to nearly $5.7 billion by 2028. The information in this report is a must-read for a number of professionals in the AI and pharmaceutical sectors.

To learn more or make a purchase, visit BCC Research.

Download Report Overview

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts' goal is to help you make informed business decisions, free of noise and hype.

Contact Us

Corporate HQ:
BCC Research LLC
49 Walnut Park, Building 2
Wellesley, MA 02481, USA
info@bccresearch.com
+1 781-489-7301

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/unlocking-the-future-of-drug-discovery-with-artificial-intelligence-301934565.html